Ignite Creation Date:
2024-05-05 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 9:53 AM
Study NCT ID:
NCT00731744
Status:
UNKNOWN
Last Update Posted:
2008-08-11
First Post:
2008-08-07
Brief Title:
Generation of Dendritic Cell Precursors From Cord Blood Stem Cells
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Generation of Dendritic Cell Precursors From Cord Blood Stem Cells
Status:
UNKNOWN
Status Verified Date:
2008-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is a growing interest in generating dendritic cells DCs for using as vaccines Several cytokines especially stem cell factor SCF and FLT3-ligand FL have been identified as essential to produce large numbers of myeloid precursors and even to increase DC yield obtained by the action of granulocyte-macrophage colony-stimulating factor GM-CSF and tumor necrosis factor alpha TNF-α However there are few studies on the effect of the early-acting cytokines commonly used to expand CD34 progenitor cells on DC generation
We have established a serious of functional analysis of maturated or immaturated DCs including surface markers screening or cytokine production Here we design this two-year project to evaluate the possible methodology in the generation of CD14CD1a- and CD14- CD1a myeloid DC precursors from CD34 cells In the first year of the project we will set up the standard protocol to generate DC precursors from cord blood stem cells In the first step we will isolate CD34 cells from cord blood and amplify these cells Purity of the CD34 cell populations obtained will be greater than 90 In the next step these primary cultures of CD34 cells will treat with early-acting cytokines such as GM-CSF and IL-4 to further induction into dendritic cells Functional analysis of dendritic cells would be performed in this stage In the second year of the project we will further evaluate the induction of DCs by CD34 stem cells could be affected by combination of mesenchymal stromal cells These results of this research with CD34-based DCs induction provide the basis for materials to develop the DC-based vaccine against viral and fungal infections and might be a powerful tool in anti-tumor immunotherapy
We have established a serious of functional analysis of maturated or immaturated DCs including surface markers screening or cytokine production Here we design this two-year project to evaluate the possible methodology in the generation of CD14CD1a- and CD14- CD1a myeloid DC precursors from CD34 cells In the first year of the project we will set up the standard protocol to generate DC precursors from cord blood stem cells In the first step we will isolate CD34 cells from cord blood and amplify these cells Purity of the CD34 cell populations obtained will be greater than 90 In the next step these primary cultures of CD34 cells will treat with early-acting cytokines such as GM-CSF and IL-4 to further induction into dendritic cells Functional analysis of dendritic cells would be performed in this stage In the second year of the project we will further evaluate the induction of DCs by CD34 stem cells could be affected by combination of mesenchymal stromal cells These results of this research with CD34-based DCs induction provide the basis for materials to develop the DC-based vaccine against viral and fungal infections and might be a powerful tool in anti-tumor immunotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None